Growth Spurt: Pediatric Labeling Is On The Rise, Taxing US FDA Safety Monitoring

The US FDA Pediatric Advisory Committee uses web-posted reviews of “low safety risk” products to keep up with postmarketing monitoring requirements amid rising interest in pediatric development.

pediatrics
Pediatric safety labeling changes continue to grow. • Source: Shutterstock

Using a streamlined process to fulfill its legislative obligation, the US Food and Drug Administration’s Pediatric Advisory Committee declared routine, ongoing postmarket safety monitoring appropriate for 35 drug and biologic products.

Key Takeaways
  • The FDA’s Pediatric Advisory Committee uses a streamlined web-posted review process to deal with large numbers of “low safety risk” pediatric products.

Prior to an 18 September meeting, committee members reviewed the FDA’s assessment that the postmarketing monitoring for each product did...

More from Drug Safety

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.